In Vitro Diagnostics (IVD) Partnering Deals, Worldwide, 2014-2020 - Access to Headline, Upfront, Milestone and Royalty Data

DUBLIN, May 14, 2020 /PRNewswire/ -- The "Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020" report has been added to's offering.

This report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

    --  In-depth understanding of In Vitro Diagnostics deal trends since 2014
    --  Access to headline, upfront, milestone and royalty data
    --  Analysis of the structure of In Vitro Diagnostics agreements with
        numerous real life case studies
    --  Detailed access to actual In Vitro Diagnostics contracts entered into by
        leading biopharma companies
    --  Identify most active In Vitro Diagnostics dealmakers since 2014
    --  Insight into terms included in a In Vitro Diagnostics partnering
        agreement, with real world examples
    --  Understand the key deal terms companies have agreed in previous deals
    --  Undertake due diligence to assess suitability of your proposed deal
        terms for partner companies

The report takes the reader through a comprehensive review In Vitro Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering In Vitro Diagnostics partnering deals.

The report presents financial deal term values for In Vitro Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the In Vitro Diagnostics partnering field; both the leading deal values and most active In Vitro Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 430 online deal records of actual In Vitro Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of In Vitro Diagnostics dealmaking.

    --  Chapter 1 provides an introduction to the report
    --  Chapter 2 provides an overview of the trends in In Vitro Diagnostics
        dealmaking since 2014, including details of headline, upfront, milestone
        and royalty terms.
    --  Chapter 3 provides a review of the leading In Vitro Diagnostics deals
        since 2014. Deals are listed by headline value. Where the deal has an
        agreement contract published at the SEC a link provides online access to
        the contract.
    --  Chapter 4 provides a comprehensive listing of the top 25 most active
        companies in In Vitro Diagnostics dealmaking with a brief summary
        followed by a comprehensive listing of In Vitro Diagnostics deals
        announced by that company, as well as contract documents, where
    --  Chapter 5 provides a comprehensive and detailed review of In Vitro
        Diagnostics partnering deals signed and announced since Jan 2014, where
        a contract document is available in the public domain. Each deal title
        links via Weblink to an online version of the deal record and contract
        document, providing easy access to each contract document on demand.
    --  Chapter 6 provides a comprehensive and detailed review of In Vitro
        Diagnostics partnering deals signed and announced since Jan 2014. The -
        Chapter is organized by specific In Vitro Diagnostics technology type.
        Each deal title links via Weblink to an online version of the deal
        record and where available, the contract document, providing easy access
        to each deal on demand.

A comprehensive series of appendices is provided organized by In Vitro Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in In Vitro Diagnostics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of In Vitro Diagnostics technologies and products.

Available deals are listed by:

    --  Company A-Z
    --  Headline value
    --  Stage of development at signing
    --  Deal component type
    --  Specific therapy target
    --  Technology type

Analyzing actual contract agreements allows assessment of the following:

    --  What are the precise rights granted or optioned?
    --  What is actually granted by the agreement to the partner company?
    --  What exclusivity is granted?
    --  What is the payment structure for the deal?
    --  How are sales and payments audited?
    --  What is the deal term?
    --  How are the key terms of the agreement defined?
    --  How are IPRs handled and owned?
    --  Who is responsible for commercialization?
    --  Who is responsible for development, supply, and manufacture?
    --  How is confidentiality and publication managed?
    --  How are disputes to be resolved?
    --  Under what conditions can the deal be terminated?
    --  What happens when there is a change of ownership?
    --  What sublicensing and subcontracting provisions have been agreed?
    --  Which boilerplate clauses does the company insist upon?
    --  Which boilerplate clauses appear to differ from partner to partner or
        deal type to deal type?
    --  Which jurisdiction does the company insist upon for agreement law?

Companies Mentioned

    --  3PrimeDx
    --  10X Genomics
    --  23andMe
    --  36 Strategies General Trading
    --  A*STAR Institute of Microelectronics (IME)
    --  AB Analitica
    --  Abbott Laboratories
    --  Abcam
    --  Abionic
    --  Access BIO
    --  Accuscience
    --  AceCGT Life Science
    --  Acon Labs
    --  Actelion
    --  ADT Altona Diagnostic Technologies
    --  Advanced Biological Laboratories
    --  Advanced Cooling Therapy
    --  Aerocrine
    --  Aethlon Medical
    --  Agena Bioscience
    --  Agendia
    --  Agilent Technologies
    --  Air Force General Hospital
    --  AirStrip Technologies
    --  AIT Laboratories
    --  Akers Biosciences
    --  AKSA Medical
    --  Alere
    --  ALK-Abello
    --  AllerGenis
    --  Alliance Pharma
    --  ALR Technologies
    --  Al Zahrawi Medical Supplies
    --  Amarantus BioSciences
    --  A Menarini Diagnostics
    --  America's Choice Provider Network
    --  American Pathology Partners
    --  AmpTec
    --  AMRA
    --  Amydis Diagnostics
    --  Anixa Biosciences
    --  Appistry
    --  Appriss Health
    --  Ariosa Diagnostics
    --  Arkray
    --  Arkray USA
    --  Arno Therapeutics
    --  Arquer Diagnostics
    --  Arterial Health International
    --  ASPiRA Labs
    --  Association for Frontotemporal Degeneration
    --  AstraZeneca
    --  AstraZeneca HealthCare Foundation
    --  Astute Medical
    --  Asuragen
    --  ATGen Global
    --  Atomo Diagnostics
    --  Austrian Institute of Technology
    --  AVL Sofia
    --  Axonlab
    --  AyoxxA Biosystems
    --  Aytu BioScience
    --  Baker IDI Heart and Diabetes Institute
    --  Banc De Sang I Teixits
    --  Banyan Biomarkers
    --  BASF
    --  Baxter International
    --  Bayer
    --  Bayer Healthcare
    --  Baylor College of Medicine
    --  Beckman Coulter
    --  Beijing Clear Biotech
    --  Beijing Leadman Biochemistry
    --  Bestmed
    --  Better Living Now
    --  Beurer
    --  Bill and Melinda Gates Foundation
    --  Bio-Manguinhos
    --  Bio-Rad Laboratories
    --  Bio-Techne
    --  bioAffinity Technologies
    --  Biocartis
    --  Biocept
    --  BioFire Diagnostics
    --  Biohit
    --  Biomedical Advanced Research and Development Authority
    --  BIOMEDX Group
    --  BioMed X Innovation Center
    --  bioMerieux
    --  Biomnis
    --  Bioportugal Quimica Farmaceutica
    --  Biotage
    --  BioTelemetry
    --  BioVendor
    --  Bioventix
    --  Biozym Scientific
    --  Bird Foundation
    --  Blood Centers of America
    --  Bluejay Diagnostics
    --  BMV Medica
    --  Bode Technology
    --  Boehringer Ingelheim Vetmedica
    --  Bonnie J. Addario Lung Cancer Foundation
    --  Boston Scientific
    --  Boston University
    --  Boston University School of Medicine
    --  Breakthrough Diagnostics
    --  Broad Institute
    --  Burnet Institute
    --  Cambridge Bioscience
    --  Cambridge Cognition
    --  Cancer Genetics
    --  Canon U.S. Life Sciences
    --  Capnia
    --  Caputron Medical
    --  CARB-X
    --  CardiNor
    --  CardioDx
    --  CardioLogic
    --  Cardiorentis
    --  CareDx
    --  Care GB Plus
    --  Carl Zeiss Meditec
    --  Case Western Reserve University
    --  CBD Vida
    --  Celgene
    --  Cellgen Diagnostics
    --  Cell Marque
    --  Centaur
    --  Center for Connected Health
    --  Center for Human Genetics and Laboratory Medicine
    --  Centers for Disease Control and Prevention
    --  Cepheid
    --  Cernostics
    --  Chembio Diagnostics
    --  Children's Hospital Boston
    --  Children's Hospital Oakland Research Institute (CHORI)
    --  Chun Fo Pharmaceutical
    --  CIRCA Scientific

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets